About
Technology
Issues
FAQ
Links
Official Page
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.